X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rheumatology (139) 139
humans (123) 123
index medicus (123) 123
rheumatoid arthritis (113) 113
female (86) 86
male (82) 82
arthritis, rheumatoid - drug therapy (79) 79
antirheumatic agents - therapeutic use (69) 69
tumor necrosis factor-alpha - antagonists & inhibitors (62) 62
middle aged (59) 59
abridged index medicus (56) 56
etanercept (47) 47
arthritis (43) 43
aged (41) 41
treatment outcome (40) 40
adult (39) 39
epidemiology (39) 39
infliximab (39) 39
methotrexate (35) 35
severity of illness index (34) 34
disease (32) 32
registries (31) 31
cohort studies (30) 30
antirheumatic agents - adverse effects (29) 29
care and treatment (27) 27
juvenile idiopathic arthritis (27) 27
prospective studies (27) 27
rheumatoid-arthritis (27) 27
adalimumab (26) 26
1506 (25) 25
risk factors (25) 25
clinical science (24) 24
efficacy (24) 24
safety (24) 24
therapy (24) 24
tumor necrosis factor (24) 24
patients (23) 23
tumor necrosis factor-tnf (22) 22
anti-tnf (21) 21
child (20) 20
research (20) 20
validation (20) 20
arthritis, rheumatoid - genetics (19) 19
musculoskeletal diseases (19) 19
united kingdom (19) 19
adolescent (18) 18
clinical and epidemiological research (18) 18
risk (18) 18
anti-tnf therapy (17) 17
antibodies, monoclonal - therapeutic use (17) 17
british-society (17) 17
drug therapy (17) 17
immunoglobulin g - therapeutic use (17) 17
polymorphism, single nucleotide (17) 17
receptors, tumor necrosis factor - therapeutic use (17) 17
studies (17) 17
united kingdom - epidemiology (17) 17
antirheumatic agents (16) 16
arthritis, rheumatoid - epidemiology (16) 16
criteria (16) 16
biological products - therapeutic use (15) 15
children (15) 15
dmards (15) 15
rheumatoid factor (15) 15
rituximab (15) 15
dosage and administration (14) 14
health risk assessment (14) 14
incidence (14) 14
mortality (14) 14
predictors (14) 14
remission (14) 14
antibodies, monoclonal, humanized (13) 13
child, preschool (13) 13
disease-activity (13) 13
health aspects (13) 13
pediatric rheumatology (13) 13
tnf inhibitors (13) 13
analysis (12) 12
arthritis, juvenile - drug therapy (12) 12
complications and side effects (12) 12
metaanalysis (12) 12
population (12) 12
skin and connective tissue diseases (12) 12
antibodies, monoclonal - adverse effects (11) 11
association (11) 11
disease activity (11) 11
follow-up studies (11) 11
genetic aspects (11) 11
necrosis factor therapy (11) 11
biologics (10) 10
cancer (10) 10
monoclonal-antibody (10) 10
outcomes (10) 10
physiological aspects (10) 10
prognosis (10) 10
register (10) 10
antirheumatic agents - administration & dosage (9) 9
arthritis, juvenile - diagnosis (9) 9
arthritis, rheumatoid - complications (9) 9
biological products - adverse effects (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Rheumatology, ISSN 1462-0324, 04/2018, Volume 57, Issue suppl_3
Journal Article
Rheumatology, ISSN 1462-0324, 04/2019, Volume 58, Issue Supplement_3
Journal Article
Rheumatology, ISSN 1462-0324, 04/2019, Volume 58, Issue Supplement_3
Journal Article
Rheumatology, ISSN 1462-0324, 04/2017, Volume 56, Issue suppl_2
Journal Article
Rheumatology, ISSN 1462-0324, 04/2017, Volume 56, Issue suppl_2
Journal Article
Rheumatology, ISSN 1462-0332, 04/2015
Journal Article
Rheumatology, ISSN 1462-0324, 04/2014, Volume 53, Issue suppl_1, pp. i7 - i7
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2018, Volume 77, Issue 6, pp. 905 - 910
ObjectivesTo compare the incidence of serious infection (SI) across biologic drugs used to treat rheumatoid arthritis (RA) using data from the British Society... 
dmards (biologic) | infections | epidemiology | rheumatoid arthritis | BACTERIAL-INFECTIONS | ADALIMUMAB | EFFICACY | SAFETY | MONOCLONAL-ANTIBODY | RHEUMATOLOGY | FACTOR-ALPHA | TOCILIZUMAB | TUMOR-NECROSIS-FACTOR | INCREASED RISK | DOUBLE-BLIND | Follow-Up Studies | Humans | Middle Aged | Male | Infliximab - therapeutic use | Opportunistic Infections - chemically induced | Incidence | Certolizumab Pegol - adverse effects | Infliximab - adverse effects | Arthritis, Rheumatoid - drug therapy | Sensitivity and Specificity | Antirheumatic Agents - adverse effects | Adult | Biological Products - adverse effects | Female | Registries | Certolizumab Pegol - therapeutic use | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Antibodies, Monoclonal, Humanized - adverse effects | Etanercept - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Opportunistic Infections - epidemiology | Risk Factors | Arthritis, Rheumatoid - epidemiology | Aged | United Kingdom - epidemiology | Etanercept - therapeutic use | Drugs | Bacterial infections | Intravenous administration | Biological products | Mortality | Rheumatology | Infections | Tumor necrosis factor-α | Patients | Meta-analysis | Polypharmacy | Etanercept | Antibiotics | Rheumatoid arthritis | Questionnaires | Monoclonal antibodies | TNF inhibitors | Sepsis | Tumor necrosis factor-TNF
Journal Article
Journal Article
PLoS genetics, ISSN 1553-7390, 2013, Volume 9, Issue 3, p. e1003394
Journal Article
Journal Article
Arthritis Research and Therapy, ISSN 1478-6354, 12/2016, Volume 18, Issue 1, p. 282
Journal Article
Arthritis Research and Therapy, ISSN 1478-6354, 07/2018, Volume 20, Issue 1, pp. 147 - 11
Background: Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first choice in rheumatoid arthritis (RA) but response varies. Predicting... 
Response | Methotrexate | Rheumatoid arthritis | Prediction model | CRITERIA | DEPRESSION | MONOTHERAPY | EFFICACY | ANXIETY | VALIDATION | RHEUMATOLOGY | PHARMACOGENETIC MODEL | HEALTH-ASSESSMENT QUESTIONNAIRE | REMISSION | Drug therapy | Testing | Studies | Illnesses | Anxieties | Rheumatology | Questionnaires | Rheumatism | Patients
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.